SubHero Banner

Veklury® (remdesivir) – Expanded indication

On January 20, 2022, the FDA approved Gilead’s Veklury (remdesivir), for the treatment of coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older and weighing at least 40 kg) with positive results of direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing, who are not hospitalized and have mild-to-moderate COVID-19, and are at high risk for progression to severe COVID-19, including hospitalization or death.

Download PDF